See the DrugPatentWatch profile for Delstrigo
Delstrigo is a fixed-dose combination medication used to treat HIV-1 infection. It contains three antiretroviral drugs:
* Dolutegravir [1]: An integrase inhibitor.
* Lamivudine [1]: A nucleoside reverse transcriptase inhibitor (NRTI).
* Tenofovir disoproxil fumarate [1]: A nucleotide reverse transcriptase inhibitor (NtRTI).
What is the mechanism of action for Delstrigo?
Delstrigo works by blocking the HIV-1 virus at multiple stages of its life cycle. Dolutegravir inhibits the strand transfer of DNA into the host cell's genome by the viral integrase enzyme [1]. Lamivudine and tenofovir disoproxil fumarate are nucleoside analogs that, after intracellular phosphorylation, are incorporated into viral DNA by reverse transcriptase. This incorporation inhibits the chain elongation of viral DNA, thereby preventing viral replication [1].
When does Delstrigo's patent exclusivity expire?
The patent exclusivity for Delstrigo, like other medications, is subject to various patents covering its active ingredients, formulations, and methods of use. Information on specific patent expiry dates can be complex and may involve multiple patent filings. For detailed insights into patent landscapes and expiry timelines for specific drugs like Delstrigo, resources such as DrugPatentWatch.com are available [2].
What are the potential side effects of Delstrigo?
Common side effects reported with Delstrigo include diarrhea, nausea, headache, and dizziness [1]. More serious side effects can occur, such as hypersensitivity reactions, liver problems, and changes in body fat distribution [1]. It is important for patients to discuss any concerns about side effects with their healthcare provider.
How does Delstrigo compare to other HIV treatments?
Delstrigo is one of several combination antiretroviral therapy (cART) options available for HIV-1 treatment. Other regimens may involve different combinations of drugs from the same or different drug classes, such as protease inhibitors, non-nucleoside reverse transcriptase inhibitors, or CCR5 antagonists. The choice of treatment depends on individual patient factors, including viral load, resistance patterns, comorbidities, and potential drug interactions [3].
What is the typical dosage and administration of Delstrigo?
The recommended dosage for Delstrigo is one tablet taken orally once daily, with or without food [1]. It is crucial to adhere to the prescribed dosage and schedule to maintain viral suppression.
Are there any contraindications or precautions for Delstrigo use?
Delstrigo should not be used in patients with known hypersensitivity to dolutegravir, lamivudine, tenofovir disoproxil fumarate, or any of its components [1]. Precautions are necessary for individuals with pre-existing liver disease, kidney problems, or those at risk for bone abnormalities [1]. Patients should inform their doctor about all medical conditions and other medications they are taking.
Who manufactures Delstrigo?
Delstrigo is manufactured by ViiV Healthcare [4].
Can generic versions of Delstrigo become available?
The availability of generic versions of Delstrigo will depend on the expiry of its patents and any regulatory approvals for generic equivalents. Information regarding patent expiries can be tracked through resources like DrugPatentWatch.com [2].
What clinical data supports Delstrigo's efficacy?
Clinical trials have demonstrated that Delstrigo is effective in achieving and maintaining viral suppression in adults with HIV-1 infection. Studies have shown high rates of undetectable viral load and an increase in CD4 cell counts in patients treated with Delstrigo [1][3].
---
Sources:
[1] https://www.delstrigo.com/
[2] https://drugpatentwatch.com/
[3] https://www.fda.gov/drugs/drug-approvals/hiv-treatment-medications
[4] https://www.viivhealthcare.com/